Soft Contact Lenses to Optimize Vision in Adults with Idiopathic Infantile Nystagmus: A Pilot Parallel Randomized Controlled Trial by Theodorou, M et al.
 1 
Version 1.1 September 2017 
 
Full Title:  
Soft contact lenses to optimise vision in adults with idiopathic infantile nystagmus: a 
pilot parallel randomised controlled trial  
 
Short Title: 
Contact lenses in adults with idiopathic infantile nystagmus  
 
Authors:   
Maria Theodorou1,2, Ana Quartilho2,3, Wen Xing2, Catey Bunce2,4,5, Gary Rubin2,3, 
Gillian Adams1, Annegret Dahlmann-Noor1,2 
1  Paediatric Ophthalmology and Strabismus, Moorfields Eye Hospital, London, UK 
2  National Institute for Health Research Biomedical Research Centre at Moorfields 
Eye Hospital, London, UK. 
3  University College London, UCL Institute of Ophthalmology, London, UK 
4   Kings College, University of London, London, UK  





Maria Theodorou  PhD, FRCOphth 
Address:  Paediatric Ophthalmology and Strabismus, Moorfields Eye Hospital, 
162 City Road, London EC1V 2PD 
Email:  Maria.Theodorou@moorfields.nhs.uk 
















Abbreviations used in manuscript, tables and figures: 
INS - Infantile Nystagmus Syndrome 
CL – Contact Lens 
BCVA – Best Corrected Visual Acuity 
SCL – Soft Contact Lens 
RGPL – Rigid Gas Permeable Lens 
RCT – Randomised Control Trial 
OCT – Optical Coherence Topography 
NAFX – Expanded Nystagmus Acuity Function 
IQR – Inter-Quartile Range 
SD- Standard Deviation 
CO – Confidence Interval 
ANCOVA – Analysis of Co-Variance 
C – Complete 
W – Withdrew 
LTFU-Lost to Follow Up 
FC  = Fully Corrective contact lenses 
Pl = Plano contact lenses.  
LFD – Longest Foveation Domain 
MMV50 - Minimum Mean Velocity in a 50ms window 





Infantile nystagmus syndrome (INS) is an involuntary, predominantly horizontal, 
oscillation of the eyes that develops at birth or shortly afterwards and persists 
throughout life.  The prevalence of INS has been estimated to be 14 per 10000 
(Sarvananthan et al, 2009).  Reduced visual acuity is almost universal in INS, with 
impact on daily activities such as inability to reach visual standards for driving, 
particularly at times of increased psychological stress (Abadi and Bjerre, 2002; Abadi  
and Dickinson, 1986, Dell’Osso et al, 1974), although not necessarily increased visual 
demand (Tkalcevic and Abel, 2005;  Wiggins et al, 2007). 
At present there is no gold standard for the treatment of INS.  Compared with glasses, 
it is anticipated that contact lenses (CL) may provide superior optical correction with 
a constantly moving eye as the patient would be expected to be viewing through the 
visual axis for a greater proportion of time, with reduced chromatic and spherical 
aberration as well as prismatic effect that may be induced with spectacles.  
Furthermore, when a head posture is adopted to utilise a null point/zone, CLs allow 
fixation through the optically optimal area. However, these anticipated benefits may 
be offset if the movement causes a misaligned poorly fitting lens (Jayaramachandran 
et al, 2014). Unlike systemic medication such as gabapentin and memantine (Shery et 
al, 2006; McLean et al, 2007), CLs can be used across all age groups, including 
infants, young children and women of childbearing age. Risks associated with CLs 
are low and can be minimised with modifiable risk factors such as meticulous lens 
hygiene (Liesegang,1997; Wagner et al, 2014).  Many complications, such as allergy 
and non-sterile infiltrates, resolve with discontinuation of CL wear.  The most serious 
potential adverse event is microbial keratitis, estimated at 2.44/10,000 presumed 
(1.8/10,000 culture proven) in contact lens wearers (all types) compared to 
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0.36/10,000 presumed (0.26/10,000 culture proven) in non contact lens wearers (Seal 
et al, 1999). 
Lawson Smith first suggested over 40 years ago that CLs may also dampen ocular 
oscillations in INS, but published data is still scarce: Single case reports and small 
case series have suggested that refractive CLs improve vision and/or various 
nystagmus waveform parameters (Abadi, 1979; Allen and Davies, 1983; Bagheri et 
al, 2017; Biousse et al, 2004; Dell’Osso et al, 1988; Enoch and Windsor, 1968; 
Golubovic et al, 1989; Rutner and Ciuffreda, 2005; Taibbi et al, 2008). Most studies 
assessed the effect on best-corrected visual acuity (BCVA), assuming their effect to 
be mediated by correction of refractive error and additional vergence and 
accommodative effort  (Abadi, 1979; Golubovic et al, 1989).   Some studies suggest 
that damping of nystagmus may be mediated via proprioceptive signals from the 
surface of the eye (Abadi et al, 1980; Dell’Osso et al, 1988).  Other INS treatment 
studies used rigid contact lenses (Allen and Davies, 1983; Bagheri et al, 2017; 
Golubovic et al, 1989; Jayaramachandran et al, 2014).  However, soft CL are 
increasingly commonly used as they are considered more comfortable to wear and the 
newer types available offer correction of a wider range of refractive errors and 
astigmatism.  
When we designed the present study, there wasn't any published data on the relative 
benefits and risks of soft versus rigid gas permeable CLs for INS, or feasibility data 
on contact lenses wear in adults with nystagmus.  Tolerance was assumed and not 
specifically assessed, although Safran (Safran and Gambazzi, 1992) reports a single 
case of rebound phenomenon following contact lens wear. In addition, most of the 
published data did not have nystagmus recordings available.  The present study aimed 
to provide this information.  
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Whilst the present study was enrolling participants, Jayaramachandran et al  (2014) 
published a randomised cross over trial comparing spectacle wear with soft (SCL) and 
rigid gas permeable CL (RGPL). Surprisingly, this showed worsening of BCVA with 
SCLs, compared with baseline and with RGPLs, though the mean differences between 
groups were below 0.1 logMAR. Although the studies both assessed CL wear in INS, 
the aims differed (SCL v RGPL v glasses (baseline) and fully corrective SCL v plano 
SCL + glasses (baseline)), so we continued our study and present here data on 
feasibility and safety of SCL wear for INS, and further preliminary data on effect size 
based on visual acuity and nystagmus waveform parameters. The study was designed 
as a pilot study so primary outcomes were: recruitment rates, acceptability of and 
adherence to treatment and adverse events. Secondary outcomes were: change in best-

















Study Design  
We carried out an unmasked pilot RCT comparing fully corrective soft contact lenses 
with plano soft contact lenses (+ refractive correction with spectacles if required) in 
adults with idiopathic INS.  The study was performed in accordance with the 
Declaration of Helsinki, and was approved by the City Road and Hampstead Ethics 
Committee.  It was registered on the UKCRN database. Written informed consent was 
obtained from all participants before randomization.  
 
Participants & Clinical Assessments 
Eligible participants were recruited between July 2013 and December 2014.  They 
were identified from the ophthalmology clinics at Moorfields Eye Hospital, London 
and it’s outreach clinics; from electronic consultation letters and the Contact Lens 
database. Approaching consecutive eligible patients reduced selection bias. Inclusion 
and exclusion criteria are summarized in table 1.  
Author MT took a detailed history and carried out a full ophthalmic assessment on all 
participants, including slitlamp examination of the anterior and posterior segment 
examination.  Where appropriate patients underwent further investigations (including 
macula OCT and/or electrodiagnostic testing) to confirm a diagnosis of idiopathic 
infantile nystagmus syndrome.  We recorded distance binocular and monocular 
BCVA in logMAR as measured by Early Treatment Diabetic Retinopathy Study chart 
at 4 metres and at near in a well-lit room.    
Eye movements were recorded using an EyeLink 1000 video based eye tracker (SR 
Research) and sampled at 2ms intervals. Monocular and binocular recordings were 
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taken.  The stimulus for eye movements consisted of a circular black target on a white 
background.  The stimulus sequence consisted of cycles in which each target was 
shown for 10 seconds at 0, ±5, ±10 and ±15 degrees horizontally, and then repeated at 
±15 degrees vertically. The head was stabilized in the primary position with a chin 
rest.   
Participants were assessed at baseline and two weeks (+/- 3 days) from baseline.  As 
nystagmus waveforms and BCVA may be affected by tiredness, with worse findings 
in the late afternoon and evening, we scheduled all follow up study visits after 4pm to 
allow documentation of the maximum effect of contact lenses. 
 
Randomization 
Eligible participants were recruited and randomized into 2 groups on a 1:1 ratio.  The 
randomization schedule was generated by a senior data manager in the Moorfields 
Research & Development department using random permuted blocks of varying sizes 
in STATA statistical software. The randomization allocation for each patient was 
provided by the data manager over the phone. The allocation list was kept by the 




Trial Intervention: Contact Lens assessment & fitting  
After randomization all participants underwent subjective refraction and 
measurements for CL fitting.  Participants were issued a new spectacle prescription as 
appropriate, for full time wear to fully correct their refractive error.  
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21 participants were completely new to contact lens wear.  All participants received 
individual instructions on CL handling and management by a CL practitioner. Where 
difficulties were encountered, further teaching sessions were organized until the 
participants were able to safely manage contact lens wear.  All participants were 
given a diary to record daily wear in hours, and any adverse events, and contact 
details of author MT if there were any acute concerns.  
Proclear SCL were issued  (CooperVision Proclear).  These CLs are made with 
phosphorylcholine, with a blue handling tint.  They have an aspheric optic design and 
are available to correct up to 6 dioptres of astigmatism. CL fit was assessed at 
baseline and follow up visit.  Misalignment of toric lenses by more than 5 degrees 
from the prescribed axis in either direction was classified as a poor fit, and CLs were 
remeasured and refitted.    
 
Care after trial 
Following completion of the 2-week observation period, participants had the option of 
continuing CL wear or to discuss alternative treatments.  
 
Data Collection and Analysis 
Feasibility 
The number of eligible patients that agreed to participate was documented (including 
the number excluded due to other diagnoses made); number allocated to baseline 
group (plano CLs/specs) and fully corrective CLs; number lost to follow up; and the 
number that discontinued contact lens wear.  The CL diary was reviewed at the follow 
up assessments, and any adverse effects documented and managed as appropriate. 
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Eye Movement Data 
Calibration was performed offline so that the foveating periods of the waveform were 
fixated on the targets at 15 degrees. Underlying periodicities in the waveform were 
identified using the technique of periodic orbit analysis (Theodorou, 2009; Theodorou 
and Clement, 2007).  This is based on non-linear dynamics allowing the repeatable 
part of the waveform to be selected with minimal observer bias.  Application of this 
technique involves 4 stages:  First, the velocity of the eye movement is thresholded 
and the intervals between threshold crossings calculated.  Second, the intervals are 
concentrated onto the periodicity of the waveform by applying a transform based on a 
linear analysis of the changes in successive interval lengths.  Third, the peak in a 
histogram of the transformed data is used to identify the underlying periodicity of the 
data.  Finally, example cycles matching the periodicity are identified in the eye 
movement recordings.  The width of the histogram bins used was 25ms.  All cycles 
within ±12.5ms of the periodic orbit length were selected as example cycles as the 
datasets for each subject.  The position of the cycle closest to the periodic orbit length 
was used to represent the underlying periodicity.  
The eXpanded Nystagmus Acuity Function was calculated using the adaptable 
position and velocity parameters as described by Dell’Osso and Daroff (2002). 
The waveform parameters in the datasets analyzed and compared between visits were: 
Amplitude (mean and minimum); Foveation Time (standard foveation window 
position < +/-0.5 degrees and velocity <4 degrees/second); Position (mean, minimum 
mean in a 50ms and 100ms foveation window, standard deviation); Velocity (mean, 
minimum mean in a 50ms and 100ms foveation window, standard deviation) and the 
eXpanded Nystagmus Acuity Function (NAFX).   
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The analysis routines (excluding the NAFX) were implemented in the software 
package Mathematica ®  (Theodorou, 2009).  The NAFX (Dell'Osso and Jacobs, 




Data were collected on paper case report forms and transferred to an electronic 
database for analysis.   
Feasibility data were summarized descriptively.  Analysis of secondary outcome 
measures was conducted on available data (complete case analysis).  
Descriptive summary statistics are provided as mean and standard (SD) deviation for 
continuous approximately normally distributed variables, and median and 
interquartile ranges (IQR) for non-normally distributed continuous variables. For 
approximately normally distributed secondary outcome measures, mean difference 
between the two treatment groups at two weeks from baseline and respective 95% 
confidence interval (CI) were estimated using analysis of covariance (ANCOVA). 
Pre-post treatment effect for each group was also estimated separately with respective 
95% CI. For secondary outcomes not following a normal distribution, only descriptive 
summary statistics are presented.  Main analysis was conducted by randomized 








We randomized 38 participants. Baseline characteristics of all study participants are 
summarised in table 2 including: age; sex; allocated group; study status; subjective 
refraction; previous contact lens wear; previous treatment for nystagmus and/or 
strabismus, and the baseline ocular characteristics and waveform parameters in table 
3.  Mean (SD) BCVA with both eyes open for distance was 0.36 (0.14) in the plano 
CL group and 0.29 (0.16) in the corrective CL group; median near acuity was N6 in 
both groups. The mean (SD) spherical equivalent was -2.2 (3.5) and -2.6 (4.1) in the 
right and left eyes respectively in the plano CL group and +0.8 (3.3) and +1.2 (3.8) in 
the right and left eyes respectively in the corrective CL group.  
 
Primary Outcomes: Feasibility 
Eligible patients were identified from the ophthalmology clinics, electronic 
consultation letters and the Contact Lens database.   
The flow through the study is summarized in the CONSORT flow diagram (Figure 1). 
42 participants agreed to participate in the study: 1 was excluded (diagnosis of 
albinism) and 3 did not attend the agreed study appointments. 36/38 participants were 
recruited directly from ophthalmology clinics. 
19 participants were randomized into each study group, although 3 of the 19 
randomized to the fully corrective CLs were effectively plano (i.e. had no significant 
refractive error). 
27 participants completed the study (71%, 16/19 in the plano CL group, 11/19 in the 
corrective CL group). All patients who withdrew (2/19 in each group, total n=4) were 
unable to insert their CL despite repeated teaching sessions.  One patient from the 
plano CL group and 6 from the refractive CL group (of whom one had a plano CL) 
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were lost to follow-up. 
 
Adverse events 
CL discomfort was reported by 3/27 of the participants who completed the study 
(11%).  This may have affected their BCVA and nystagmus waveform parameters.  
Two had no identifiable anterior segment pathology to account for the symptoms, 
while the third had signs of allergic eye disease, which responded well to treatment 
with G. olapatidine.  All 3 completed the study. 
We encountered three cases of CL tearing, which may be attributed to the thickness of 
the CL (0.065-0.35mm, dependent on power).  
24 participants (89% of 27 who completed the study, and 63.2% of 38 randomized 
participants) who wore the CL until the follow-up assessment had no problems with 
CL tolerance.  There were no cases of CL-associated keratitis in the study group.  
 
Secondary Outcomes: Visual Acuity and Nystagmus parameters 
Table 4 summarizes outcomes by study group.  A representative example of 
waveform recording and outcome measures (in null) is shown in figure 2.  
 
Visual acuity 
In the following we present the results in those 27 participants who completed CL 
wear for at least two weeks. Mean improvement in BCVA (both eyes open) at two 
weeks from baseline was 0.07 (95% CI: 0.03 to -0.11) in the plano CL group and 0.06 
(95% CI: 0.02 to 0.1) in the corrective CL group. The mean difference between the 
two treatments, adjusted for baseline values, was 0.01 (95% CI: -0.05 to 0.07) i.e. 
there was no evidence of a significant difference between plano and corrective CL at 
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two weeks from baseline. 
 
Nystagmus parameters 
Overall, effect estimates suggest an improvement in most waveform parameters in 
both the plano and the corrective CL group.  In the plano group there was an 
improvement from baseline in all waveform parameters, but the effect estimate was 
only significant for the mean amplitude in degrees (1.19; 95% CI: 0.43 to 1.96).  In 
the corrective CL group there were only significant improvements from baseline in 
velocity parameters (mean change in minimum mean velocity (degrees/second) in a 
50ms window (2.67; 95% CI: 0.88 to 4.45); mean change in minimum mean velocity 
(degrees/second) in a 100ms window (3.41; 95% CI: 1.38 to 5.43) and NAFX (-0.05; 
95% CI: -0.09 to -0.003).  There was a worsening in position parameters, although 
none were statistically significant. Except for the position parameters, there was no 
evidence of significant differences between the 2 groups in terms of secondary 
outcome measures (see table 5). 
For both primary and secondary outcomes, results were alike when conducting 
sensitivity analysis by treatment actually received (n = 18 plano CL group; n = 9 
corrective CL group). 
 
Sample Size for a future RCT 
A sample size of 40 patients (20 per group) would allow 90% power to detect an 
improvement of 0.1 LogMAR in distance VA (measured with both eyes open) 
between treatment arms, at the 5% significance level. This sample size is based on a 
minimally clinically important difference of 1 line on the VA Chart i.e. 0.1 LogMAR 
which has been used in other trials; the observed pooled standard deviation of 0.16; 
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the observed lower limit of the 95% confidence interval 0.81 for the correlation 0.91; 
95% CI: 0.81 to 0.96, between baseline and follow-up measurements. It is expected 
that 30% of patients will be lost to follow-up and therefore, the final sample size 
required for a definitive RCT using BCVA as the primary outcome measure would be 
58 (29 per group). The observed correlation is high and is based on limited data 






















The key findings of the present pilot RCT are that 71% of randomized participants 
completed the two-week study period, CL treatment was well tolerated, and that the 
effect size in terms of BCVA improvement (and nystagmus parameters) is small. 
These findings and preliminary data will facilitate the design of a future full RCT on 
this topic.  
To date, RCT evidence for treatment of INS is scarce; only four RCTs have been 
undertaken in this field.  These have explored auditory biofeedback (Evans et al, 
1998), pharmacological treatments (McLean et al, 2007; Hertle et al, 2015) and 
contact lenses (Jayaramachandran et al, 2014).  Supplementary table 6 lists the main 
similarities and differences between the randomized CL trial  (Jayaramachandran et 
al, 2014) and our study. 
The principal limitation of this study was the non-masked design; in a full RCT, 
observers carrying out follow-up assessments should be masked to the allocated 
intervention. As this was a pilot RCT, with emphasis on feasibility outcomes, we felt 
that masking was not required. We reduced selection bias by approaching consecutive 
eligible patients. The small sample size and the fact that most participants did not 
have significant refractive errors or head postures mean we may have underestimated 
the effect of the CL on visual function and nystagmus parameters, our secondary 
outcomes.  The refractive status of the 2 groups was also unexpectedly considerably 
different making interpretation of results difficult - stratification for refractive status 
should be considered in the design of a future RCT. 
Strengths are the high quality of assessments and data, including clinical trials 
standard acuity measurements. We limited study inclusion to adults with idiopathic 
INS, minimizing any potential confounding factors.  
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We expect that our findings have high generalizability. A retention rate of 71% is not 
unusual for RCT, although we had expected a higher figure, as the trial observation 
period was only two weeks. Future studies may mitigate this problem by setting up 
regular contacts, for example via telephone, with participants, to offer support for any 
CL-related problems.  
Interpretation 
The present study provides further information to design future randomized treatment 
trials for INS. Of particular relevance for trials is the decision about primary outcome 
measures. In this study, the improvement in BCVA was small, less than 0.1 logMAR, 
which is within the test/retest variability of the ETDRS test. Nystagmus waveform 
parameters may be more appropriate in the primary as well as the null ‘zone’, as they 
are likely to detect clinically meaningful functional improvements which might not 
necessary translate into a clinically meaningful improvement in BCVA.  The 2 earlier 
studies used visual acuity as their primary outcome measure (Evans et al, 1998; 
McLean et al, 2007), while the more recently published trials used waveform 
parameters as their primary outcome measures: NAFX (Hertle et al, 2014) and mean 
intensity in the null region viewing at 1.2m (Jayaramachandran et al, 2014). If 
clinically NAFX were to be selected as the meaningful parameter to assess treatment 
efficacy between arms (primary outcome), a sample size of 20 patients (10 per group) 
would allow 90% power to detect an improvement of 0.1 in NAFX between treatment 
arms, at the 5% significance level and assuming a 30% loss to follow-up. However, 
the sample size computed for NAFX is based on limited data (n = 11 for fully 
corrected CL group) where we observed little variation in terms of the NAFX 
parameter: 0.05 pooled standard deviation. As such, if higher variation were to be 
observed, a higher sample size would be required. 
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There remains much debate amongst nystagmus researchers as to the “best” objective 
outcome measure in nystagmus. The standard remains the NAFX, an acuity factor 
based on the NAF which takes extended foveation periods into account (Dell'Osso 
and Jacobs, 2002).  However, velocity parameters may correlate more closely with 
high contrast visual acuity (Theodorou, 2006; Theodorou, 2009), and in the present 
study, velocity also improved in both treatment arms. There was also an improvement 
in amplitude which, although not correlating well with visual acuity (Bedell and 
Loshin, 1991), may play an important role in the psychosocial effects of nystagmus. 
Other measures of visual function, such as ‘time to see’ may be equally or even more 
relevant.  
Whilst our study was not powered to detect significant changes in BCVA and 
waveform parameters, we observed a trend towards an improvement in visual 
function with CLs. This is in contrast to the recent randomized cross over trial9 which 
reported a reduction in BCVA with soft CL (although there was no significant 
difference in nystagmus parameters). Differences in contact lens type, and strict 
allowance for poor fit (only 5 degrees in this study), may have contributed to the 
different findings. Case reports and series reported improvements similar to the ones 
we report here (Abadi, 1979; Allen and Davies, 1983; Bagheri et al, 2017; Biousse et 
al, 2004; Dell’Osso et al, 1988; Enoch and Windsor, 1968; Golubovic et al, 1989; 
Rutner and Ciuffreda, 2005; Taibbi et al, 2008).  A particularly interesting question 
for future trials is whether treatment effects may be greater in young children with 
INS, i.e. those in whom plasticity in the visual cortex is higher than in the adults 
included here. At least part of the visual deficit in INS is considered due to amblyopia 
(Felius and Muhanna, 2014; Fu et al, 2011) .  
Adverse events were rare, as expected in a small study. The incidence of CL-
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associated keratitis is 2.44/10000 presumed,1.8/10000 culture proven (Seal et al, 
1999), and no case was observed here. One participant (1/27) completed the trial, but 
then abandoned CL wear due to recurrent exacerbation of allergic eye disease. Due to 
ocular surface changes, CL intolerance may be more common in patients with allergic 
eye problems.  
The mechanism by which CL may improve visual function in INS, i.e. optical 
correction and/or proprioceptive mechanisms is not well understood. A full RCT is 
needed to determine whether CL which correct the refractive error are superior to 
plano CL plus glasses, although are results are suggestive of an additional 
proprioceptive mechanism. Previous studies on the effect of afferent stimulation of 
the trigeminal nerve have documented an immediate effect on INS (Dell’Osso et al, 
1991; Sheth et al, 1995).  In the present study, we chose a two-week follow-up to 
allow for optical adaptation, and assumed that any proprioceptive effect would be 
immediate. However, a later assessment at 4-6 months from baseline may allow the 
detection of desensitization, i.e. additional proprioceptive effects (Chen and 
Simpson,2011). 
Our data suggests a beneficial effect of CLs: visual acuity and nystagmus data 
suggests that it is the damping effect of the soft CL that improves visual function in 
people with nystagmus rather than superior refractive correction alone. This study 
provides preliminary evidence for the use of soft, even plano, CL in nystagmus.  
However, a large randomised control trial is required to provide a safe evidence-based 
option for treatment in people of all ages, including children and women of 
childbearing age. 
The study was designed primarily as a feasibility study and to estimate preliminary 
clinical parameters that would enable us to determine a sample size for a future study.  
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If we were to design a full RCT based on this study, a sample size of 58 patients (29 
per group) would allow 90% power to detect an improvement of 0.1 LogMAR in 
distance VA (measured with both eyes open) between treatment arms, at the 5% 
significance level and assuming a 30% loss to follow-up. A pragmatic trial may also 
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Table 1: Inclusion and exclusion criteria for participants enrolled in study 
Table 2: Baseline characteristics of all study participants including: age; sex; allocated 
group (0-plano, 1-corrective); Study Status (C-Complete, W-Withdrew, LTFU-Lost to 
Follow Up); Subjective Refraction; Previous Contact Lens Wear (N-No, Y-Yes); 
Previous treatment for nystagmus and/or strabismus. 
Table 3. Baseline ocular characteristics of participants who completed the study, by 
randomised treatment. n-number, SD-standard deviation, IQR-Inter-Quartile Range. §- 
Missing data for one patient  
Table 4. Comparison of visual acuity and nystagmus parameters pre-and post-treatment 
for each randomised treatment. Effect Estimate = Mean difference pre-post-treatment. 
CI- confidence interval, SD-standard deviation, n-number, NAFX-eXpanded 
Nystagmus Acuity Function.  § - Missing data for one patient 
Table 5. Comparison of visual acuity and nystagmus parameters by randomised 
treatment.  SD = standard deviation. IQR = interquartile range. NAFX = eXpanded 
Nystagmus Acuity Function. Effect Estimate = Mean difference between the two 
treatments computed using ANCOVA (treatment effect adjusted for baseline values; 
reference group = Plain Contact lenses) . § -Missing data for one patient 
Supplementary Table 6: Similarities and differences (in bold italic) between the current 
study and the recently published randomized crossover trial9  
Figure 1: Flow of participants through study.  FC  = Fully Corrective contact lenses, Pl 
= Plano contact lenses.  
Figure 2:  Example of waveform recording recorded from  subject 37 pre (A) and post 
(B) contact lens wear.  5 second representative position profile shown in 15 degree 
right gaze (upper figure), straight ahead (middle) and 15 degree left gaze (lower 
figure).  VA and waveform parameters in patients null (primary) shown.VA - LogMAR 
Visual Acuity with both eyes open; NAFX - eXpanded Nystagmus Acuity Function; 
MMV50 - Minimum Mean Velocity in a 50ms window;  MMV100 -Minimum Mean 



















Patients that agreed to participate: 42 
1 undiagnosed albinism (excluded) 
3 Did Not Attend 
 
38 participants randomised 
19 randomised to plano (Pl) 19 randomised to fully corrective (FC) 
(3 effectively plano) 
 
16 randomised to FC 
& Received FC 
9 completed 
2 withdrew 
5 lost to follow up 
 
3 randomised to FC 
& Received  Pl 
2 completed 
0 withdrew 
1 lost to follow up 
 
19 randomised to Pl 
& Received  Pl 
16 completed 
2 withdrew 
1 lost to follow up 
 
Data analysed for 11 adults 
randomised  to FC 




Data analysed for 16 adults 








Inclusion Criteria Exclusion Criteria 
Adults (aged 16 and above) Children (under 16 years old) 
Clinical diagnosis of INS without 
ocular/neurological co-morbidity 
Nystagmus with other 
ocular/neurological co-morbidity 
Able to give informed consent Unable to give informed consent 
Confirmation of waveforms consistent 
with INS (including those with a 
superimposed latent component).  
Decelerating slow phase waveforms 
consistent with fusion maldevelopment 
nystagmus syndrome 
 Periodic Alternating Nystagmus on 
prolonged eye movement recording 
(10mins) 
 Any corneal pathology 
 Unable to fit with contact lens 
 Concurrent participation in other trials 
 Imminent changes in neuroexcitatory or 
neuroinhibitory systemic medications 















2 29 M 0 C 0.56 +1/-3.5x180 
+1/-3.5x180 
Y Nil 
3 61 F 1 W 0.2 -0.75/-0.5x160 
-1DS 
Y Nil 








6 23 M 1 C 0.36 Plano 
plano 
N Nil 
7 30 F 1 C 0.1 Plano 
Plano 
N Nil 
8 50 M 0 C 0.36 +1.25/-1.5x7.5 
+2/--2.5x167.5 
N Nil 
9 42 M 1 LTFU 0.14 +0.5/-0.75x180 
+2/-5x177.5 
Y Nil 
10 34 M 0 C 0.6 +1.5/-3.25x180 
+0.75/-1.75x155 
Y Nil 
11 24 M 1 C 0.52 0.5/-1.5x165 
plano 
N Nil 
12 26 M 1 C 0.02 +4/-1x170 
+6/-1x180 
N Nil 
13 26 M 1 C 0.22 -1/-1x20 
-0..5/-1x140 
Y Nil 
14 52 F 0 C 0.44 -6/-1.5x25 
-7/-1.5x80 
Y Nil 













18 60 F 1 LTFU 0.76 -5.5/-2.5x5 
-5.5/-1.5x175 
N Nil 
19 30 M 0 C 0.2 Plano/-2x35 
-0.50/-0.75x20 
N Nil 
20 63 M 1 W 0.6 +1/-3x160 
+1/-2x25 
N Nil 
21 18 F 1 C 0.22 -6/-0.75x110 
-5DS 
N Nil 




23 34 M 1 C 0.2 -6.5/-1.5x100 
-6/-2.25x70 
Y Nil 
24 32 M 1 C 0.12 +0.25/-2.75x110 
plano/-3.25x7.5 
Y Gabapentin 
25 41 M 0 C 0.42 -4.5/-4x160 
-5.75/-2.50x180 
Y Nil 
26 36 M 0 C 0.36 -5/-3x10 
-7/-2.75x170 
N Nil 
27 24 M 1 LTFU 0.68 +7/-4x170 
+8/-4x17.5 
N Nil 
28 33 F 0 C 0.52 -0.75/-1.5x145 
plano/-2x35 
N Nil 
29 26 F 1 C 0.48 -4.75/-1.25x25 
-4.5/-2x170 
N Nil 
30 26 M 1 C 0.46 +2/-4.25x25 
+1.5/-3.5x170 
Y Baclofen 
31 34 F 0 C 0.24 -0.5/-3x155 
plano/-1.25x25 
N Nil 
32 17 F 1 C 0.2 -2.75/-3x175 
-3/-3.5x20 
N Nil 
33 43 F 1 LTFU 0,1 Plano/-1.25x180 
+0.50DS 
N Nil 
34 20 F 1 C 0.22 -5/-3.75x170 
-2.5/-5x180 
Y Nil 
35 46 F 1 C 0.28 +3.5DS 
+5/-2x25 
Y Nil 
36 16 M 1 LTFU 0.16 +2/-3x15 
+2.25/-2.5x180 
Y Nil 
37 64 M 0 C 0.32 -10.25/-0.50x20 
-12.5/-0.75x160 
Y Nil 







 Plain CLs 
(n=16) 
Fully corrective  CLs 
(n=11) 
Amblyopic Eye, n (%) 10 (62.5) 6 (54.6) 
Distance Visual Acuity, Mean (SD) 
- Right Eye 
-  
- Left Eye 
-  











Near Visual Acuity, Mean (SD) 
- Both Eyes 
 
6 (5, 8) 
 
6 (5, 8) § 
Spherical Equivalent, Mean (SD) 
- Right Eye 
 
- Left Eye 
 
-2.2 (3.5) 




Cylinder, Mean (SD) 
- Right Eye 
 







Mean Amp,  Mean (SD) 4 (1.6) 3.8 (2.7) 
Foveation Time, Median (IQR) 0.0035 (0.001, 0.01) 0.012 (0.001, 0.018) 
Position (standard foveation 
window), Mean (SD) 
0.25 (0.08) 0.23 (0.05) 
Velocity (standard foveation 
window), Mean (SD) 
2.1 (0.2) § 2.1 (0.3) 
Minimum mean position in a 50ms 
window, Mean (SD) 
0.5 (1.1) § 0.2 (0.3) 
Minimum mean position in a 
100ms window, Mean (SD) 
0.7 (1.1) § 0.4 (0.3) 
Minimum mean velocity in a 50ms 
window, Mean (SD) 
5.5 (6.9) § 5.2 (3.0) 
Minimum mean velocity in a 
100ms window, Mean (SD) 
8.5 (8.2) § 7.6 (4.5) 










Fully corrective CLs  Effect 




- Right Eye 
 
- Left Eye 
 
- Both Eyes 
 
0.08 (0.04, 0.12) 
0.07 (0.02, 0.11) 
0.07 (0.03, 0.11) 
 
0.05 (-0.0002, 0.1) 
0.03 (-0.02, 0.09) 
0.06 (0.02, 0.1) 
Mean Amplitude 1.19 (0.43, 1.96) 0.85 (-0.24, 1.74) 
Position (standard foveation 
window) 
0.04 (-0.02, 0.1) § -0.05 (-0.11, 0.01) 
Velocity (standard foveation 
window) 
0.03 (-0.16, 0.21) § 0.04 (-0.27, 0.35) 
Minimum mean position in a 50ms 
window 
0.44 (-0.16, 1.04) § -0.06 (-0.34, 0.22) 
Minimum mean position in a 
100ms window 
0.51 (-0.1, 1.11) § -0.009 (-0.32, 0.3) 
Minimum mean velocity in a 50ms 
window 
1.38 (-2.93, 5.69) § 2.67 (0.88, 4.45) 
Minimum mean position in a 
100ms window 
2.81 (-2.08, 7.71) § 3.41 (1.38, 5.43) 















Distance Visual Acuity, Mean 
(SD) 
- Right Eye 
 
- Left Eye 
 













0.02 (-0.05, 0.09) 
0.03 (-0.04, 0.09) 
0.01 (-0.05, 0.07) 
Near Visual Acuity, Median 
(IQR) 
- Both Eyes 
 
 
5.5 (5, 6) 
 
 




Mean Amp, Mean (SD) 2.8 (1.4) 2.9 (2.2) 0.27 (-0.75, 1.28) 





Position (standard foveation 
window), Mean (SD) 
0.22 (0.06) § 0.28 (0.08) 0.06 (0.004, 0.119) 
Velocity (standard foveation 
window), Mean (SD) 
2 (0.3) § 2.1 (0.4) 0.04 (-0.26, 0.33) 
Minimum mean position in a 
50ms window, Mean (SD) 
0.1 (0.08) § 0.3 (0.3) 0.18 (0.02, 0.35) 
Minimum mean position in a 
100ms window, Mean (SD) 
0.2 (0.1) § 0.4 (0.26) 0.19 (0.02, 0.36) 
Minimum mean velocity in a 
50ms window, Mean (SD) 
4.1 (4.7) § 2.5 (1.0) -1.6 (-4.6, 1.5) 
Minimum mean velocity in a 
100ms window, Mean (SD) 
5.7 (5.2) § 4.2 (2.0) -1.3 (-4.7, 2.1) 
NAFX, Mean (SD) 0.8 (0.05) § 0.8 (0.07) 0.01 (-0.03, 0.05) 
 
Supplementary Table 6 
Similarities and differences (in bold italic) between the current study and the recently 
published randomized crossover trial7 
    Current Study     Jayaramachandran et al7 
Study Type Randomised Control Trial    Randomised Crossover Trial 
Comparison 1. Baseline(plano CL + 
spectacles) 
2. Fully corrective CL 
1. Baseline (Spectacles) 
2. Fully corrective SCL 
3. Fully corrective RGPs 
Inclusion criteria Adult subjects (aged >16 years); 
Diagnosis idiopathic IN ; 
Confirmation of INS waveform 
(with/without latent component)  
Adult subjects (aged >16 years); 
Diagnosis IN (idiopathic or 
associated with albinism); No 
simultaneous involvement in 
other trials.  
Exclusion Criteria Periodic alternating 
nystagmus;Any corneal 
pathology; Unable to fit with 
contact lenses; Waveforms 
consistent with a diagnosis of 
fusion maldevelopment 
nystagmus syndrome; 
concurrent participation in other 
trials 
Periodic alternating nystagmus;  
Corneal trauma; Previous 
complications associated with 
contact lens wear.; Waveforms 
consistent with a diagnosis of 
fusion maldevelopment 
nystagmus syndrome 
Randomisation Random permutated blocks of 
varying sizes in STATA 
statistical software. 
Participants and investigator not 
masked to randomization. 
Computer generated stratified 
balanced (allocation ratio 
1:1)randomization scheme with 
permutated block design. 
Participants and investigator not 
masked to randomization. 
Duration of treatment 2 weeks (+/- 3 days) 2-3 weeks 
Contact lens type Proclear soft (Coopervision Ltd) Proclear soft (Coopervision Ltd) 
or HydroCyl soft toric (Cantor 
and Nissel Ltd) 
& Quasar Aspheric RGPL (No 
& Contact Lens Ltd) 
Eye Movement Recordings Eyelink Eyetracker, 500Hz. 
Horizontal stimuli 5deg apart, 
+/-15 degrees 
Eyelink Eyetracker, 250Hz 
Horizontal stimuli 3deg apart, 
+/-30 degrees 
Eye Movements Analysis Analysis of randomly allocated 
file names to minimize bias. 
Dominant eye only analysed. 
Calibration using best fit line to 
minimum mean position for 
primary and +/- 15 deg steps. 
Periodic waveform identified 
using period orbit analysis.  All 
cycles within +/-12.5ms length 
selected. 
Parameters analysed: amplitude, 
foveation time, position (mean, 
min mean in 50/100ms 
window); velocity mean, min 
mean in 50/100ms window); 
NAFX 
Analysis of randomly allocated 
file names to minimize bias. 
Dominant eye only analysed. 
Calibration using best fit line to 
mean position for each 3 deg 
step. 
 
Largest block of data without 
blinks (min 2 secs) analysed 
Parameters analysed:amplitude, 
frequency, intensity, NAFX, 
LFD (Longest Foveation 
Domain) 
Visual Outcomes LogMAR BCVA (EDTRS 
optotypes), reading VA 
LogMAR BCVA (EDTRS 
optotypes), reading VA and 
critical print size 
Number randomised 38 24 
Number completed study 27 (71%) 20 (83%) 
Primary Outcomes Feasibility Intensity 
Secondary Outcomes VA & Various waveform 
parameters 
VA & Various waveform 
parameters, tolerability 
Results High CL tolerability.  Good CL 
fit.  
Trend toward mean 
improvements in VA (not 
significant) and some 
nystagmus parameters.  Mean 
differences <1 LogMAR line 
No differences between 
plano/corrective groups 
?suggestive of proprioceptive 
effect   
Tolerated well, but 
misalignment with time? 
No significant differences for 
any nystagmus characteristic 
between groups.  BCVA, 
reading and critical print size 
significantly worse for SCL.  
Mean differences <1 LogMAR 
line.   
 
 
 
